Dr. Tezcan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
900 Blake Wilbur Dr
Palo Alto, CA 94304Phone+1 650-723-4000Fax+1 650-498-5840- Is this information wrong?
Education & Training
- University at BuffaloFellowship, Hematology and Medical Oncology, 1994 - 1995
- University of British ColumbiaHematology, 1992 - 1994
- University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1992
- Istanbul University FomClass of 1986
Certifications & Licensure
- CA State Medical License 2012 - 2026
- WA State Medical License 1992 - 2026
- ID State Medical License 1995 - 2025
- MO State Medical License 2019 - 2025
- OR State Medical License 2020 - 2025
- NE State Medical License 2019 - 2024
- NY State Medical License 1995 - 1997
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
- Holmes Award Idaho Women’s Health, 2005
- Evelyn Martin Memorial Fellowship 1988
- Join now to see all
Clinical Trials
- Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls" Start of enrollment: 2017 Jun 30
Publications & Presentations
PubMed
- 12 citationsEarly Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors.Andrew M. Davis, Wade T. Iams, David Chan, Michael S. Oh, Robert W. Lentz, Neil Peterman, Alex Robertson, Abhik Shah, Rohith Srivas, Timothy R. Wilson, Nicole J. Lambe...> ;Molecular Cancer Therapeutics. 2020 Jan 1
- 12 citationsImpact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.Baruch Brenner, Ravit Geva, Megan P. Rothney, Alexander Beny, Ygael Dror, Mariana Steiner, Ayala Hubert, Efraim Idelevich, Alexander Gluzman, Ofer Purim, Einat Shacham...> ;Value in Health. 2016 Jan 1
- 16 citationsValidation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and III Rectal Cancer PatientsMarlies S. Reimers, Peter J. K. Kuppen, Mark Lee, Margarita Lopatin, Haluk Tezcan, Hein Putter, Kim M. Clark-Langone, Gerrit-Jan Liefers, Steve Shak, Cornelis J.H. van...> ;Journal of the National Cancer Institute. 2014 Nov 1
- Join now to see all
Journal Articles
- Validation of the 12-Gene Colon Cancer Recurrence Score as a Predictor of Recurrence Risk in Stage II and III Rectal Cancer PatientMarlies S. Reimers MS, Kuppen PJK, Lee M, Lopatin M, Tezcan H, Putter H, Clark-Langone K, Liefers GJ, Shak S, and van de Velde CJH, JNCI J Natl Cancer Inst , 1/1/2014
- Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from A...Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A, Oncologist, 1/1/2012
- DNA Methylation in Lung CancerTezcan H, NEJM, 1/1/2008
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- The 12-gene colon cancer assay: summary of clinical evidenceBurke E, Tezcan H, Lopatin M, Clark-Langone K, Lee M, Shak S, Sing A, ASCO GI Symposium, 1/1/2014
- Prospective evaluation of a 12-gene assay on patient treatment decisions and physician confidence in mismatch repair-proficient (MMR-P) stage IIa colon cancer patientsAlberts SR, Renfro LA, Lopatin M, Tezcan H, Sloan J, Chao C, Lee M, ASCO GI Symposium, 1/1/2014
- Global quantitative measures using next-generation sequencing for breast cancer presence outperform individual tumor markets in plasmaBeasley EM, Abramson RD, Alexander GE, Chan D, Bradley K, Collin F, Crager M, Dei Rossi A, Dorado J, Friedman A, Gibb WJ, Jeong J, Jones C, Ku CJ, Ma Y, Morlan J, Qu K..., SABCS, 1/1/2014
- Join now to see all
Press Mentions
- Lexent Bio Announces Use of Its Liquid Biopsy Assay, Confera Dx, in a Peer-Reviewed Paper Published in the Journal Molecular Cancer TherapeuticsMay 14th, 2020
- Liquid Biopsies Intensify Surveillance of ctDNASeptember 3rd, 2019
Professional Memberships
- Member
- Member
- Member
- IASLCMember
Other Languages
- German, Turkish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: